Amebiasis Global Market Report 2025

Amebiasis is an intestinal infection caused by the parasite *Entamoeba histolytica*, often resulting in symptoms such as diarrhea, abdominal pain, and, in some cases, liver abscesses. This infection is treated with medications such as metronidazole and tinidazole, which work by targeting the parasite in both the gut and tissues.

The primary drugs used to treat amebiasis include metronidazole, paromomycin, and tinidazole. Metronidazole is an antibiotic that eliminates certain bacteria and parasites by disrupting their DNA, making it an effective treatment for amebiasis. The medications can be administered through various routes, including oral and intravenous, and are commonly used in healthcare settings such as hospitals and pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The amebiasis market research report is one of a series of new reports from The Business Research Company that provides amebiasis market statistics, including the amebiasis industry global market size, regional shares, competitors with the amebiasis market share, detailed amebiasis market segments, market trends, and opportunities, and any further data you may need to thrive in the amebiasis industry. This amebiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The amebiasis market size has grown strongly in recent years. It will grow from $0.82 billion in 2024 to $0.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increasing incidence of amoebic infections in tropical regions, poor sanitation and hygiene practices in developing countries, increasing international travel, especially to endemic areas, growing awareness about the disease, and lack of access to clean drinking water in rural areas.

The amebiasis market size is expected to see strong growth in the next few years. It will grow to $1.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising prevalence of immune-compromised populations, increasing government initiatives to improve sanitation and healthcare infrastructure, growing investments in research for new treatments, increasing focus on health initiatives to combat parasitic diseases, and growing demand for effective oral medications. Major trends in the forecast period include growing adoption of combination therapies, development of vaccines, advancements in drug delivery systems, advancements in pharmaceutical research, and development of novel antiprotozoal drugs.

The forecast of 6.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. infectious disease treatment by inflating prices of nitroimidazole antibiotics and diagnostic Polymerase Chain Reaction(PCR) kits developed in India and Belgium, resulting in delayed parasite identification and higher tropical medicine costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of parasitic infections is expected to drive the growth of the amebiasis market. Parasitic infections are caused by organisms such as protozoa, helminths, or ectoparasites that live on or inside a host, deriving nutrients at the host's expense. Various factors, including increased travel, climate change, poor sanitation, and growing drug resistance, contribute to the spread and persistence of these infections. Amebiasis, caused by the Entamoeba histolytica parasite, plays a significant role in parasitic infections by invading the intestines and leading to symptoms such as diarrhea, abdominal pain, and severe complications such as tissue damage and liver abscesses. For example, in January 2024, the Animal and Plant Health Agency, a UK-based government agency, reported 1,071 cases of Parasitic Gastroenteritis (PGE) in 2022, including 190 cases of haemonchosis and 95 cases of nematodirosis. The number of haemonchosis cases was notably higher than in the previous year. As a result, the increasing prevalence of parasitic infections is fueling the expansion of the amebiasis market.

The widespread issue of poor sanitation is also contributing to the growth of the amebiasis market. Poor sanitation, which includes inadequate access to clean water, improper sewage disposal, and unhygienic facilities, facilitates the spread of infectious diseases. The lack of proper waste management, insufficient infrastructure, rapid urbanization, and limited access to clean water, especially in developing regions, are key factors driving the prevalence of poor sanitation. Amebiasis thrives in such conditions, as contaminated water and food sources create an environment conducive to the spread of the Entamoeba histolytica parasite. For instance, in July 2023, the United Nations Water agency reported that in 2022, 2 billion people lacked access to basic hygiene services, while 3.5 billion did not have safely managed sanitation. This widespread issue continues to drive the demand for solutions in the amebiasis market.

Leading companies in the amebiasis market are focusing on innovative advancements such as ready-to-use oral liquid metronidazole to enhance patient compliance and treatment effectiveness. This pre-prepared liquid antibiotic formulation is designed to simplify treatment, particularly for individuals who have difficulty swallowing pills. In November 2023, Kesin Pharma Corporation, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for Likmez (metronidazole) oral suspension, 500 mg/5 mL. This marks the first ready-to-use oral liquid formulation of metronidazole. The oral suspension provides a pediatric-friendly alternative, making it easier for children to take the medication with accurate dosing, thereby improving adherence to treatment protocols. Additionally, the liquid formulation offers dosing flexibility, allowing healthcare providers to tailor treatment based on the severity of infections and individual patient needs.

Major players in the amebiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Cepheid Inc., Mission Pharmacal Company, Profounda Inc., and Zydus Lifesciences Limited.

North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in amebiasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the amebiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The amebiasis market includes revenues earned by entities by providing services such as medical consultation and treatment management, vaccination and preventive services, pharmaceutical services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The amebiasis market also includes sales of antiprotozoal medications, diagnostic kits, vaccines, and probiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Amebiasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on amebiasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for amebiasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The amebiasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Metronidazole; Paromomycin; Tinidazole
• 2) By Route Of Administration: Oral; Intravenous
• 3) By Application: Hospital; Pharmacy
• Subsegments:
• 1) By Metronidazole: Oral Metronidazole; Intravenous Metronidazole; Combination Therapy with Metronidazole
• 2) By Paromomycin: Oral Paromomycin; Paromomycin in Combination with Other Drugs
• 3) By Tinidazole: Oral Tinidazole; Tinidazole for Severe Infections
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sanofi SA; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Novartis AG; F. Hoffmann-La Roche Ltd; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Boehringer Ingelheim International GmbH; Siemens Healthineers AG; Becton Dickinson and Company; Teva Pharmaceutical Industries Ltd.; Cipla Limited; Hikma Pharmaceuticals PLC; Lupin Limited; Cepheid Inc.; Mission Pharmacal Company; Profounda Inc.; Zydus Lifesciences Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.